GlassScriptPhysician profile
Deborah K Neitsch
NPI 1881658482
$5,677.53
in general payments reported to CMS, 2019-2025
53 companies · $627 in 2025
The $627 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $201 · 2021: $644 · 2022: $1,053 · 2023: $1,804 · 2024: $758 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,188.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,053.29 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $522.88 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.31 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $408.23 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $334.24 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $236.89 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $234.66 | 2021-2024 | Qelbree, Qelbree |
| Lilly USA, LLC | $163.53 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Corium, LLC | $138.25 | 2022-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $126.81 | 2022-2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $115.65 | 2021-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $111.41 | 2022-2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $110.90 | 2023-2025 | |
| Abbott Laboratories | $103.12 | 2019-2023 | Proclaim, Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $94.12 | 2019-2021 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Neitsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.